Biotech & Pharma

STAT+: Pharmalittle: We're reading about TrumpRx expectations, a high-dose version of Wegovy, and more

26 sec read38 views0 listens

Chris Klomp clarified that TrumpRx is not intended for most Americans with health insurance and does not imply drug price caps, while a high-dose version of Wegovy received FDA approval, offering increased weight loss potential but falling short of its competitor Zepbound. Content creators should note the nuanced messaging around healthcare policies and drug approvals to accurately inform their audiences.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Real Estate & HomeJul 2026 sec read

Nurse Lindsay Clancy Set To Go on Trial for Murder of Her 3 Children-More Than 3 Years After They Were Found Dead at Massachusetts Home

Lindsay Clancy's murder trial for killing her three children begins in Massachusetts after more than three years since the incident. The case centers on whether she should be held criminally responsible due to postpartum psychosis, a critical issue f...

Ali Nemati

Health & MedicineJun 335 sec read

STAT+: Pharmalittle: We're reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more

Cigna has announced it will no longer cover GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in its employee health plan starting July 1, pushing users to pay out-of-pocket. This development underscores the growing trend of...

Ali Nemati

Biotech & PharmaMay 1826 sec read

Drug Target for Fragile X Syndrome Identified Through Preclinical Study

UCLA Health researchers have identified EPAC2, a synaptic protein, as a potential therapeutic target for treating fragile X syndrome (FXS) through preclinical studies in mice. This discovery is significant because it addresses the excitation/inhibiti...

Ali Nemati